Home » Healthcare » Pharmaceuticals » Chronic Myeloid Leukemia (CML) Treatment Market

Chronic Myeloid Leukemia (CML) Treatment Market By Treatment Type (Tyrosine Kinase Inhibitors (TKIs), Stem Cell Transplantation, Interferon Therapy, Others); By Phase of Treatment (First-Line Treatment, Second-Line Treatment, Third-Line and Beyond); By Patient Risk Stratification (Low Risk, High Risk); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Chronic Myeloid Leukemia (CML) Treatment Market 2023	USD 7514.2 Million
Chronic Myeloid Leukemia (CML) Treatment Market, CAGR	6.20%
Chronic Myeloid Leukemia (CML) Treatment Market Size 2032	USD 12912.2 Million

Market Insights

The global demand for Chronic Myeloid Leukemia (CML) Treatment was valued at USD 7514.2 Million in 2023 and is expected to reach USD 12912.2 Million in 2032, growing at a CAGR of 6.20% between 2024 and 2032.
Tyrosine kinase inhibitors (KIs), dominate the market, and the Interferon Therapy sector is expected to develop significantly over the projection period.
Second-line treatment is the most quickly increasing segment of the Chronic Myeloid Leukemia (CML) Treatment Market; another key market area is first-line treatment.
The Chronic Myeloid Leukemia (CML) Treatment Market is dominated by the Low Risk sector, with the High Risk group also making significant contributions.
The Chronic Myeloid Leukemia (CML) Treatment Market in North America is estimated to have the biggest revenue share (38%) throughout the forecast period, followed by Europe with a 28% share by 2032. Asia Pacific is projected to expand the fastest.
Increasing healthcare spending and awareness fuels market growth.
Personalized medicine slows market growth.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Executive Summary

Market Definition

The Chronic Myeloid Leukemia (CML) Treatment Market is the industry dedicated to developing and delivering treatments for CML, a kind of cancer that affects the bone marrow and blood. This market encompasses a variety of drugs, treatments, and procedures used to manage and treat CML. The market is constantly evolving as medical research advances, resulting in better therapy options for CML patients. Pharmaceutical companies, healthcare providers, and research organizations all play important roles in fostering innovation and increasing access to therapies in this sector. The goal is to improve the quality of life and prognosis for individuals with CML by using effective and tailored treatment options.

Market Overview

The global Chronic Myeloid Leukemia (CML) Treatment Market has witnessed steady growth in recent years and is expected to grow at a CAGR of 6.20% between 2024 and 2032. The market was valued at USD 7514.2 million in 2023 and is expected to reach USD 12912.2 million in 2032.

The chronic myeloid leukemia (CML) therapy industry is undergoing considerable development and transformation, fueled by a convergence of demographic trends, technology advancements, and scientific breakthroughs. The growing prevalence of CML, particularly among the elderly, has created a greater demand for effective treatments.

This increase in demand is fueled by advances in diagnostic capabilities, which allow for the early detection and correct diagnosis of CML, extending the patient base eligible for treatment. The market’s growth is primarily driven by the introduction and success of innovative therapeutic drugs, particularly tyrosine kinase inhibitors (TKIs), which have transformed the treatment landscape by providing tailored therapy alternatives. These breakthroughs have not only improved patient outcomes

but have also sparked more research and development initiatives aimed at increasing the efficacy and lowering the negative effects of present medicines. The pharmaceutical industry’s commitment to innovation, combined with supportive regulatory settings, has continued to promote the launch of new medications and treatment modalities, highlighting a dynamic and shifting market landscape.

However, the CML treatment market faces its own set of issues, including the high prices associated with newer, more advanced medicines, which create substantial hurdles to access, particularly in low- and middle-income nations. Despite the effectiveness of current treatment choices, concerns such as resistance to therapy and unpleasant side effects persist, emphasizing the importance of continued research to develop more accessible, effective, and bearable medicines. The treatment techniques for CML have moved considerably from conventional approaches to more complex, targeted medications, with TKIs emerging as the cornerstone of treatment due to their ability to manage the illness with manageable complications. However, the therapy landscape is constantly changing, with new medications and combination regimens showing promise in reducing resistance and improving outcomes for individuals with advanced or resistant types of CML.

Segmentation by Treatment Type

Tyrosine kinase inhibitors (KIs), dominate the market due to their ability to suppress the BCR-ABL protein, which promotes leukemia cell proliferation. TKIs such as imatinib, dasatinib, and nilotinib have changed CML treatment, allowing patients to achieve long-term disease control while experiencing manageable side effects.
The Interferon Therapy sector is predicted to grow significantly throughout the forecast period.

Segmentation by Phase of Treatment

Second-Line Treatment is the most rapidly developing section of the Chronic Myeloid Leukemia (CML) Treatment Market. This market is rapidly expanding due to advances in therapy for patients who have not reacted well to earlier treatments, resulting in a renewed emphasis on finding more effective second-line treatment alternatives customized to specific patient needs.
Another major market area is first-line treatment, which is critical in laying the groundwork for overall CML care. First-line treatments are the first therapies prescribed to patients after diagnosis, with the goal of achieving remission and controlling disease progression, emphasizing the importance of early intervention and effective management strategies in improving patient outcomes in the CML treatment landscape.

Segmentation by Patient Risk Stratification

Low Risk is the most popular sector of the Chronic Myeloid Leukemia (CML) Treatment Market. This segment is well known for its importance in identifying patients with a lower risk of disease progression. It allows for more conservative treatment approaches and closely monitored management strategies, emphasizing the importance of risk stratification in guiding treatment decisions for people with CML.
The High Risk group is also a substantial market contributor.

Segmentation by Region

The Chronic Myeloid Leukemia (CML) Treatment Market in North America is expected to have the highest revenue share (38%) during the forecast period.
Europe is the second-largest market, with a predicted 28% share by 2032. Asia Pacific is expected to grow the fastest.
The rest of the world, including Latin America, the Middle East, and Africa, supplies the remaining demand for Chronic Myeloid Leukemia (CML) Treatment.

North America is predicted to have the greatest share of the worldwide market during the forecast period. Favorable reimbursement policies, high diagnostic rates, availability to advanced healthcare infrastructure, and the presence of significant players position North America to account for an estimated 38% of the market by 2032.

Moreover, Europe is the second-largest geographical market, with a projected 28% share by 2032. Growth will be driven by supportive government measures that promote research and a high rate of new product approvals. Rapidly aging populations are vulnerable to target diseases, which drives market growth.

Also, Asia Pacific is expected to develop at the fastest rate in the following years, with a 16% market share by 2032. Developing healthcare infrastructure, increased healthcare spending, rising public awareness, and massive unmet clinical needs all present promising opportunities. China and India will play an important role, thanks to their growing patient populations and disposable budgets.

Key Highlights of the Report

The global Chronic Myeloid Leukemia (CML) Treatment Market is segmented by Treatment Type, Phase of Treatment, Patient Risk Stratification, and region. In 2023, tyrosine kinase inhibitors (KIs) will dominate the market. And the Interferon Therapy sector is expected to expand dramatically. In addition, Second-Line Treatment is the most rapidly increasing portion of the market. At the same time, Low Risk is the most popular sector of the Market, with North America leading the market growth.

The Chronic Myeloid Leukemia (CML) Treatment Market is being positively influenced by advances in targeted therapies, an increase in CML cases, and a shift toward personalized medicine, all of which are contributing to the development of more effective and individualized treatment options for patients. Despite the industry’s expansion, issues such as high treatment costs, potential adverse effects of current medicines, and regulatory hurdles in the drug approval process operate as roadblocks, impeding market advancement and accessibility for people seeking CML therapy. Looking ahead, potential for market expansion include increased investments in research & development, treatment choice diversity, and continued technological developments in treatment modalities, all of which point to a positive future for CML therapy.

The Chronic Myeloid Leukemia (CML) Treatment Market in North America is expected to have the highest revenue share throughout the forecast period. Furthermore, Europe is the second-largest geographical market, while Asia Pacific is forecast to grow at the fastest rate.

What Are The Main Drivers Of The Global Chronic Myeloid Leukemia (CML) Treatment Market?

Advancements in targeted therapies are propelling the Chronic Myeloid Leukemia (CML) Treatment Market, the increasing number of CML cases, and the emphasis on personalized medicine, all contributing to the development of more effective and tailored treatment options for patients.

What Are The Major Challenges Faced By The Global Chronic Myeloid Leukemia (CML) Treatment Market?

Challenges such as high treatment costs, the potential side effects of current treatments, and regulatory hurdles in the drug approval process pose constraints on the market’s growth and accessibility, impacting the overall landscape of CML treatment.

What Are The Growth Opportunities In The Global Chronic Myeloid Leukemia (CML) Treatment Market?

The market offers opportunities for growth and improvement, including the surge in investments in research and development, the expansion of treatment choices, and the ongoing technological innovations in treatment approaches, which promise a more hopeful future for individuals battling CML.

Market Drivers

Several factors drive the global Chronic Myeloid Leukemia (CML) Treatment Market. The following are the key drivers of the global Chronic Myeloid Leukemia (CML) Treatment Market:

Increasing Healthcare Expenditures And Awareness

The global growth in healthcare expenditure is critical to the development and implementation of novel CML treatments. With more resources given to healthcare, there is more room for investment in cutting-edge research, which leads to the discovery and implementation of innovative treatment alternatives. Furthermore, increased awareness of CML among the general population and healthcare professionals results in earlier identification and treatment, which is critical for effective disease management. This increased knowledge, combined with more favorable payment regulations, makes sophisticated CML treatments available to a wider spectrum of patients. These financial and educational advancements are crucial for supporting the expansion of the CML treatment market and ensuring that patients benefit from the most recent discoveries in medical science.

Market Restraints

The global Chronic Myeloid Leukemia (CML) Treatment Market faces some challenges that may hinder its growth. These include the following:

Personalized Medicine

The development of customized medicine in the treatment of CML is a direct result of our growing understanding of the disease’s genetic foundation. Personalized medicine tailors treatment procedures to each individual’s unique genetic profile, promising even more effective and tailored treatment options. This strategy uses genetic insights to find the best therapy alternatives for each patient, with the potential to make CML treatment more efficient and outcome-oriented. As research continues to uncover the genetic complexity of CML, personalized medicine is at the forefront of revolutionary treatment techniques, providing fresh hope for targeted and effective disease management.

Opportunities

The global Chronic Myeloid Leukemia (CML) Treatment Market offers significant growth opportunities. These include the following:

Development of New and More Effective Treatments

The therapeutic environment for CML has changed dramatically, owing to considerable advances in medical research and pharmaceutical innovation. The introduction of targeted treatments, particularly tyrosine kinase inhibitors (TKIs), has transformed CML treatment. These new therapies provide a more targeted approach to fighting the cancer, targeting specific genetic markers with fewer side effects than conventional chemotherapy.

This transition to tailored therapy improves patient outcomes while also lowering the total burden of therapeutic adverse effects. The industry’s continued investment in research and development of innovative therapies demonstrates its dedication to improving the efficacy and tolerance of CML treatments, hence supporting market growth.

Competitive Landscape

Key Players

The global Chronic Myeloid Leukemia (CML) Treatment Market is highly competitive, with several key players. Some of the major players in the market and their market share are as follows:

Teva Pharmaceuticals Industries Ltd.
Incyte Corporation
Novartis AG
ARIAD Pharmaceuticals, Inc.
Stragen Pharma SA
Pfizer, Inc.
Bristol-Myers Squibb
Otsuka Pharmaceutical Co., Ltd.
Bio-Path Holdings
Prism Pharmaceuticals
Hospira, Inc.

These organizations prioritize product innovation, distribution channel expansion, and mergers and acquisitions to stay competitive.

The global Chronic Myeloid Leukemia (CML) Treatment Market’s key players continually seek to stay ahead by offering new products and developments.

In December 2021, Ascentage Pharma launched its novel medicine, Olverembatinib, in China, marking a significant milestone in the treatment of adult patients with chronic or accelerated stages of chronic myeloid leukemia (CML). Notably, Olverembatinib is the first medicine of its sort in China, manufactured by Guangzhou HealthQuest Pharma Co., Ltd., a wholly owned subsidiary of Ascentage Pharma. This launch marks a significant step forward in delivering unique therapy choices to the CML patient community in China, opening up fresh avenues for patients dealing with this difficult ailment.

In June 2023, Novartis released results from the CML SUN survey, which revealed differences in treatment goals and priorities between patients and clinicians. The survey results underscore the important need for improved communication and treatment plan customization to meet the unique needs of each patient. This data reflects a broader issue in the CML treatment landscape, underlining the significance of patient-centered care approaches.

Summary of Key Findings

The development of new and more effective treatments is the primary opportunity in the market.
Market segmented by Treatment Type, Phase of Treatment, Patient Risk Stratification, and region.
Targeted therapies, notably tyrosine kinase inhibitors (KIs), dominate the market.
Second-line treatment is the most quickly increasing part of the Chronic Myeloid Leukemia (CML) Treatment Market
North America is leading market growth; the market is highly competitive with key players including Teva Pharmaceuticals Industries Ltd., Incyte Corporation, Novartis AG, ARIAD Pharmaceuticals, Inc., Stragen Pharma SA, Pfizer, Inc. and Others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Future Outlook

Continued development of targeted therapies
Personalized treatment approaches
Focus on improving patient outcomes
Increasing research in precision medicine
Enhanced accessibility to innovative treatments

How CXOs Can Benefit from the Credence Research Chronic Myeloid Leukemia (CML) Treatment Market Report

The Credence Research Chronic Myeloid Leukemia (CML) Treatment Market Report provides CXOs with a comprehensive overview of the market, including:

Market size and growth forecast: The report provides detailed estimates of the global Chronic Myeloid Leukemia (CML) Treatment Market size, segmented by Treatment Type, Phase of Treatment, Patient Risk Stratification, and region. It also includes forecasts for the market through 2032, based on key trends and drivers.
Market segmentation: The report segments the Chronic Myeloid Leukemia (CML) Treatment Market by Treatment Type, Phase of Treatment, Patient Risk Stratification, and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
Competitive landscape: The report profiles the key players in the Chronic Myeloid Leukemia (CML) Treatment Market and provides insights into their strategies, product offerings, and financial performance. This information can help CXOs to identify and assess their competition.
Key trends and drivers: The report identifies and analyzes the key trends and drivers that are shaping the Chronic Myeloid Leukemia (CML) Treatment Market. This information can help CXOs to make informed decisions about their investments and strategies.

CXOs can use the insights from the Credence Research Chronic Myeloid Leukemia (CML) Treatment Market Report to:

Identify growth opportunities: The report can help CXOs to identify new growth opportunities in the Chronic Myeloid Leukemia (CML) Treatment Market. For example, by analyzing emerging therapies, technological advancements, and evolving patient needs, CXOs can uncover untapped market segments, explore strategic partnerships, and develop innovative solutions to address unmet medical needs in the CML treatment landscape.
Make informed investment decisions: The report can help CXOs to make informed investment decisions about Chronic Myeloid Leukemia (CML) Treatment. For example, by analyzing market trends, treatment advancements, patient demographics, and competitive landscape, CXOs can identify growth opportunities, assess potential risks, and allocate resources effectively in the CML treatment market.
Develop competitive strategies: The report can help CXOs to develop competitive strategies for their Chronic Myeloid Leukemia (CML) Treatment businesses. For example, by delving into market dynamics, competitor analysis, and regulatory landscape, CXOs can gain valuable insights to differentiate their offerings, enhance market positioning, and drive business growth in the CML treatment sector.
Track market developments: The report can help CXOs to track market developments and stay ahead of the curve. For example, the report provides insights into the latest trends and innovations in the Chronic Myeloid Leukemia (CML) Treatment Market .

Overall, the Credence Research Chronic Myeloid Leukemia (CML) Treatment Market Report is a valuable resource for CXOs who are looking to gain a deeper understanding of the market and identify opportunities for growth.

Segmentation

Treatment Type:
- Tyrosine Kinase Inhibitors (TKIs)
- Stem Cell Transplantation
- Interferon Therapy
- Others
Phase of Treatment:
- First-Line Treatment
- Second-Line Treatment
- Third-Line and Beyond
Patient Risk Stratification:
- Low Risk
- High Risk
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Chronic Myeloid Leukemia (CML) Treatment Market
2.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type
2.1.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment
2.1.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification
2.1.4. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Chronic Myeloid Leukemia (CML) Treatment Market Drivers
3.2.2. Chronic Myeloid Leukemia (CML) Treatment Market Restraints
3.2.3. Chronic Myeloid Leukemia (CML) Treatment Market Opportunities
3.2.4. Major Chronic Myeloid Leukemia (CML) Treatment Market Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Treatment Type
3.5.2. Phase of Treatment
3.5.3. Patient Risk Stratification
3.5.4. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market: Company Market Share, Value 2023
4.1.2. Global Chronic Myeloid Leukemia (CML) Treatment Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Chronic Myeloid Leukemia (CML) Treatment Market: Top 3 Company Market Share, Value 2023
4.2. Global Chronic Myeloid Leukemia (CML) Treatment Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Treatment Type Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Treatment Type Matrix
4.7. Potential for New Players in the Global Chronic Myeloid Leukemia (CML) Treatment Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and Development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Treatment Type Launch
6.5.5. Geographical Expansion
6.5.6. Butterfly Valves
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Chronic Myeloid Leukemia (CML) Treatment Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Treatment Type Mix
7.2.4. Reduced Tyrosine Kinase Inhibitors (TKIs) Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type
8.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Overview, By Treatment Type
8.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Revenue Share, By Treatment Type, 2023 Vs 2032 (in %)
8.2. Tyrosine Kinase Inhibitors (TKIs)
8.2.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By TYROSINE KINASE INHIBITORS (TKIS), By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for TYROSINE KINASE INHIBITORS (TKIS)
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Stem Cell Transplantation
8.3.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By STEM CELL TRANSPLANTATION, By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for STEM CELL TRANSPLANTATION
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Interferon Therapy
8.4.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Interferon Therapy, By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for Interferon Therapy
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Others
8.5.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Others, By Region, 2019-2032 (US$ Mn)
8.5.2. Market Dynamics for Others
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
9. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment
9.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Overview, By Phase of Treatment
9.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Revenue Share, By Phase of Treatment, 2023 Vs 2032 (in %)
9.2. First-Line Treatment
9.2.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By First-Line Treatment, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for First-Line Treatment
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Second-Line Treatment
9.3.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Second-Line Treatment, By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Second-Line Treatment
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Third-Line and Beyond
9.4.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Third-Line and Beyond, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Third-Line and Beyond
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
10. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification
10.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Overview, By Patient Risk Stratification
10.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Revenue Share, By Patient Risk Stratification,2023 Vs 2032 (in %)
10.2. Low Risk
10.2.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Low Risk, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Low Risk
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. High Risk
10.3.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By High Risk, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for High Risk
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
11. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Region
11.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Overview, by Region
11.1.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Region, 2023 Vs 2032 (in%)
11.2. Treatment Type
11.2.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032 (US$ Mn)
11.3. Phase of Treatment
11.3.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032 (US$ Mn)
11.4. Patient Risk Stratification
11.4.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032 (US$ Mn)
12. North America Chronic Myeloid Leukemia (CML) Treatment Market Analysis
12.1. Overview
12.1.1. Market Dynamics for North America
12.1.1.1. Drivers
12.1.1.2. Restraints
12.1.1.3. Opportunities
12.1.1.4. Trends
12.2. North America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032(US$ Mn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. North America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032(US$ Mn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. North America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032(US$ Mn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. North America Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2032(US$ Mn)
12.5.1. North America Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2023 Vs 2032 (in%)
12.5.2. U.S.
12.5.3. Canada
12.5.4. Mexico
13. Europe Chronic Myeloid Leukemia (CML) Treatment Market Analysis
13.1. Overview
13.1.1. Market Dynamics for North America
13.1.1.1. Drivers
13.1.1.2. Restraints
13.1.1.3. Opportunities
13.1.1.4. Trends
13.2. Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032(US$ Mn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032(US$ Mn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032(US$ Mn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. Europe Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2032 (US$ Mn)
13.5.1. Europe Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2023 Vs 2032 (in%)
13.5.2. UK
13.5.3. France
13.5.4. Germany
13.5.5. Italy
13.5.6. Spain
13.5.7. Benelux
13.5.8. Russia
13.5.9. Rest of Europe
14. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market Analysis
14.1. Overview
14.1.1. Market Dynamics for North America
14.1.1.1. Drivers
14.1.1.2. Restraints
14.1.1.3. Opportunities
14.1.1.4. Trends
14.2. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032(US$ Mn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032(US$ Mn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2032 (US$ Mn)
14.5.1. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2023 Vs 2032 (in%)
14.5.2. China
14.5.3. Japan
14.5.4. India
14.5.5. South Korea
14.5.6. South East Asia
14.5.7. Rest of Asia Pacific
15. Latin America Chronic Myeloid Leukemia (CML) Treatment Market Analysis
15.1. Overview
15.1.1. Market Dynamics for North America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2032 (US$ Mn)
15.5.1. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2023 Vs 2032 (in%)
15.5.2. Brazil
15.5.3. Argentina
15.5.4. Rest of Latin America
16. Middle East Chronic Myeloid Leukemia (CML) Treatment Market Analysis
16.1. Overview
16.1.1. Market Dynamics for North America
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2032 (US$ Mn)
16.5.1. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2023 Vs 2032 (in%)
16.5.2. UAE
16.5.3. Saudi Arabia
16.5.4. Rest of Middle East
17. Africa Chronic Myeloid Leukemia (CML) Treatment Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Africa Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2032 (US$ Mn)
17.5.1. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2023 Vs 2032 (in%)
17.5.2. South Africa
17.5.3. Egypt
17.5.4. Rest of Africa
18. Company Profiles
18.1. Teva Pharmaceuticals Industries Ltd.
18.1.1. Company Overview
18.1.2. Treatment Types/Services Portfolio
18.1.3. Geographical Presence
18.1.4. SWOT Analysis
18.1.5. Financial Summary
18.1.5.1. Market Revenue and Net Profit (2019-2023)
18.1.5.2. Business Segment Revenue Analysis
18.1.5.3. Geographical Revenue Analysis
18.2. Incyte Corporation
18.3. Novartis AG
18.4. ARIAD Pharmaceuticals, Inc.
18.5. Stragen Pharma SA
18.6. Pfizer, Inc.
18.7. Bristol-Myers Squibb
18.8. Otsuka Pharmaceutical Co., Ltd.
18.9. Bio-Path Holdings
18.10. Prism Pharmaceuticals
18.11. Hospira, Inc.
19. Research Methodology
19.1. Research Methodology
19.2. Phase I – Secondary Research
19.3. Phase II – Data Modelling
19.3.1. Company Share Analysis Model
19.3.2. Revenue Based Modelling
19.4. Phase III – Primary Research
19.5. Research Limitations
19.5.1. Assumptions

List of Figures
FIG. 1 Global Chronic Myeloid Leukemia (CML) Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Chronic Myeloid Leukemia (CML) Treatment Market Segmentation
FIG. 4 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2023 (US$ Mn)
FIG. 5 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2023 (US$ Mn)
FIG. 6 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2023 (US$ Mn)
FIG. 7 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2023 (US$ Mn)
FIG. 8 Attractive Investment Proposition, By Treatment Type, 2023
FIG. 9 Attractive Investment Proposition, By Phase of Treatment, 2023
FIG. 10 Attractive Investment Proposition, By Patient Risk Stratification, 2023
FIG. 11 Attractive Investment Proposition, by Geography, 2023
FIG. 12 Global Market Share Analysis of Key Chronic Myeloid Leukemia (CML) Treatment Market Manufacturers, 2023
FIG. 13 Global Market Positioning of Key Chronic Myeloid Leukemia (CML) Treatment Market Manufacturers, 2023
FIG. 14 Global Chronic Myeloid Leukemia (CML) Treatment Market Value Contribution, By Treatment Type, 2023 & 2030 (Value %)
FIG. 15 Global Chronic Myeloid Leukemia (CML) Treatment Market, by TYROSINE KINASE INHIBITORS (TKIS), Value, 2019-2032 (US$ Mn)
FIG. 16 Global Chronic Myeloid Leukemia (CML) Treatment Market, by STEM CELL TRANSPLANTATION, Value, 2019-2032 (US$ Mn)
FIG. 17 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Interferon Therapy, Value, 2019-2032 (US$ Mn)
FIG. 18 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 19 Global Chronic Myeloid Leukemia (CML) Treatment Market Value Contribution, By Phase of Treatment, 2023 & 2030 (Value %)
FIG. 20 Global Chronic Myeloid Leukemia (CML) Treatment Market, by First-Line Treatment, Value, 2019-2032 (US$ Mn)
FIG. 21 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Second-Line Treatment, Value, 2019-2032 (US$ Mn)
FIG. 22 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Third-Line and Beyond, Value, 2019-2032 (US$ Mn)
FIG. 23 Global Chronic Myeloid Leukemia (CML) Treatment Market Value Contribution, By Patient Risk Stratification, 2023 & 2030 (Value %)
FIG. 24 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Low Risk, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Chronic Myeloid Leukemia (CML) Treatment Market, by High Risk, Value, 2019-2032 (US$ Mn)
FIG. 26 North America Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 27 U.S. Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 28 Canada Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 29 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 30 Europe Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 31 Germany Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 32 France Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 33 U.K. Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 34 Italy Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 35 Spain Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 36 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 37 Russia Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 38 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 39 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 40 China Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 41 Japan Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 42 India Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 43 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 44 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 45 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 46 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 47 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 48 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 49 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 50 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 51 UAE Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 52 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 53 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 54 Africa Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 55 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 56 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)
FIG. 57 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, 2019-2032 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Chronic Myeloid Leukemia (CML) Treatment Market
TABLE 2 Global Chronic Myeloid Leukemia (CML) Treatment Market: Drivers Impact Analysis
TABLE 3 Global Chronic Myeloid Leukemia (CML) Treatment Market: Market Restraints Impact Analysis
TABLE 4 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Competitive Benchmarking, 2023
TABLE 5 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Key Strategies Analysis, 2023
TABLE 7 Global Chronic Myeloid Leukemia (CML) Treatment Market, by TYROSINE KINASE INHIBITORS (TKIS), By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Chronic Myeloid Leukemia (CML) Treatment Market, by TYROSINE KINASE INHIBITORS (TKIS), By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Chronic Myeloid Leukemia (CML) Treatment Market, by STEM CELL TRANSPLANTATION, By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Chronic Myeloid Leukemia (CML) Treatment Market, by STEM CELL TRANSPLANTATION, By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Interferon Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Interferon Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Chronic Myeloid Leukemia (CML) Treatment Market, by First-Line Treatment, By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Chronic Myeloid Leukemia (CML) Treatment Market, by First-Line Treatment, By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Second-Line Treatment, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Second-Line Treatment, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Third-Line and Beyond, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Third-Line and Beyond, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Low Risk, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Low Risk, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Chronic Myeloid Leukemia (CML) Treatment Market, by High Risk, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Chronic Myeloid Leukemia (CML) Treatment Market, by High Risk, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 26 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 27 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 28 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 29 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 30 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 31 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Region, 2019-2023 (US$ Mn)
TABLE 32 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Region, 2024-2032 (US$ Mn)
TABLE 33 North America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 34 North America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 35 North America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 36 North America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 37 North America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 38 North America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 39 North America Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2023 (US$ Mn)
TABLE 40 North America Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2024-2032 (US$ Mn)
TABLE 41 United States Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 42 United States Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 43 United States Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 44 United States Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 45 United States Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 46 United States Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 47 Canada Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 48 Canada Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 49 Canada Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 50 Canada Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 51 Canada Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 52 Canada Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 53 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 54 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 55 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 56 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 57 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 58 Mexico Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 59 Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 60 Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 61 Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 62 Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 63 Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 64 Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 65 Europe Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2019-2023 (US$ Mn)
TABLE 66 Europe Chronic Myeloid Leukemia (CML) Treatment Market, by Country, 2024-2032 (US$ Mn)
TABLE 67 Germany Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 68 Germany Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 69 Germany Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 70 Germany Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 71 Germany Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 72 Germany Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 73 France Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 74 France Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 75 France Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 76 France Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 77 France Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 78 France Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 79 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 80 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 81 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 82 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 83 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 84 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 85 Italy Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 86 Italy Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 87 Italy Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 88 Italy Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 89 Italy Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 90 Italy Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 91 Spain Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 92 Spain Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 93 Spain Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 94 Spain Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 95 Spain Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 96 Spain Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 97 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 98 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 99 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 100 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 101 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 102 Benelux Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 103 Russia Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 104 Russia Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 105 Russia Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 106 Russia Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 107 Russia Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 108 Russia Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 109 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 110 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 111 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 112 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 113 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 114 Rest of Europe Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 115 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 116 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 117 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 118 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 119 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 120 Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 121 China Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 122 China Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 123 China Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 124 China Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 125 China Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 126 China Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 127 Japan Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 128 Japan Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 129 Japan Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 130 Japan Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 131 Japan Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 132 Japan Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 133 India Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 134 India Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 135 India Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 136 India Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 137 India Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 138 India Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 139 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 140 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 141 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 142 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 143 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 144 South Korea Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 145 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 146 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 147 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 148 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 149 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 150 South-East Asia Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 151 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 152 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 153 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 154 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 155 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 156 Rest of Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 157 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 158 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 159 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 160 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 161 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 162 Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 163 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 164 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 165 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 166 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 167 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 168 Brazil Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 169 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 170 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 171 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 172 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 173 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 174 Argentina Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 175 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 176 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 177 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 178 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 179 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 180 Rest of Latin America Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 181 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 182 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 183 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 184 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 185 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 186 Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 187 UAE Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 188 UAE Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 189 UAE Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 190 UAE Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 191 UAE Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 192 UAE Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 193 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 194 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 195 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 196 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 197 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 198 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 199 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 200 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 201 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 202 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 203 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 204 Rest of Middle East Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 205 Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 206 Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 207 Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 208 Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 209 Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 210 Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 211 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 212 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 213 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 214 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 215 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 216 South Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 217 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 218 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 219 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 220 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 221 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 222 Egypt Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)
TABLE 223 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2019-2023 (US$ Mn)
TABLE 224 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment Type, 2024-2032 (US$ Mn)
TABLE 225 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2019-2023 (US$ Mn)
TABLE 226 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Phase of Treatment, 2024-2032 (US$ Mn)
TABLE 227 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2019-2023 (US$ Mn)
TABLE 228 Rest of Africa Chronic Myeloid Leukemia (CML) Treatment Market, By Patient Risk Stratification, 2024-2032 (US$ Mn)

Frequently Asked Questions

What is the current size of the global Chronic Myeloid Leukemia (CML) Treatment Market?

The global Chronic Myeloid Leukemia (CML) Treatment Market was valued at USD 7514.2 Million in 2023.

What is the expected growth rate of the Chronic Myeloid Leukemia (CML) Treatment Market between 2024 and 2032?

The Chronic Myeloid Leukemia (CML) Treatment Market is expected to grow at a CAGR of 6.20% between 2024 and 2032, reaching USD 12912.2 Million in 2032.

Which segment is leading the market share in terms of Treatment Type?

Tyrosine kinase inhibitors (KIs), dominate the market in 2023.

Which Patient Risk Stratification segment governs the demand for Chronic Myeloid Leukemia (CML) Treatments in the world?

The Chronic Myeloid Leukemia (CML) Treatment Market is largely controlled by the Low-Risk sector.

Who are the major players in the global Chronic Myeloid Leukemia (CML) Treatment Market?

The top players include Teva Pharmaceuticals Industries Ltd., Incyte Corporation, Novartis AG, ARIAD Pharmaceuticals, Inc., Stragen Pharma SA, Pfizer, Inc. and Others.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –